SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Falk Sörqvist Elin) "

Sökning: WFRF:(Falk Sörqvist Elin)

  • Resultat 1-10 av 24
  • [1]23Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Mansouri, Larry, et al. (författare)
  • Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.
  • 2015
  • Ingår i: Journal of Experimental Medicine. - Rockefeller University Press. - 1540-9538. ; 212:6, s. 833-843
  • Tidskriftsartikel (refereegranskat)abstract
    • NF-κB is constitutively activated in chronic lymphocytic leukemia (CLL); however, the implicated molecular mechanisms remain largely unknown. Thus, we performed targeted deep sequencing of 18 core complex genes within the NF-κB pathway in a discovery and validation CLL cohort totaling 315 cases. The most frequently mutated gene was NFKBIE (21/315 cases; 7%), which encodes IκBε, a negative regulator of NF-κB in normal B cells. Strikingly, 13 of these cases carried an identical 4-bp frameshift deletion, resulting in a truncated protein. Screening of an additional 377 CLL cases revealed that NFKBIE aberrations predominated in poor-prognostic patients and were associated with inferior outcome. Minor subclones and/or clonal evolution were also observed, thus potentially linking this recurrent event to disease progression. Compared with wild-type patients, NFKBIE-deleted cases showed reduced IκBε protein levels and decreased p65 inhibition, along with increased phosphorylation and nuclear translocation of p65. Considering the central role of B cell receptor (BcR) signaling in CLL pathobiology, it is notable that IκBε loss was enriched in aggressive cases with distinctive stereotyped BcR, likely contributing to their poor prognosis, and leading to an altered response to BcR inhibitors. Because NFKBIE deletions were observed in several other B cell lymphomas, our findings suggest a novel common mechanism of NF-κB deregulation during lymphomagenesis.
2.
  • de Miranda, Noel F. C. C., et al. (författare)
  • DNA repair genes are selectively mutated in diffuse large B cell lymphomas
  • 2013
  • Ingår i: Journal of Experimental Medicine. - 0022-1007 .- 1540-9538. ; 210:9, s. 1729-1742
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>DNA repair mechanisms are fundamental for B cell development, which relies on the somatic diversification of the immunoglobulin genes by V(D)J recombination, somatic hypermutation, and class switch recombination. Their failure is postulated to promote genomic instability and malignant transformation in B cells. By performing targeted sequencing of 73 key DNA repair genes in 29 B cell lymphoma samples, somatic and germline mutations were identified in various DNA repair pathways, mainly in diffuse large B cell lymphomas (DLBCLs). Mutations in mismatch repair genes (EXO1, MSH2, and MSH6) were associated with microsatellite instability, increased number of somatic insertions/deletions, and altered mutation signatures in tumors. Somatic mutations in nonhomologous end-joining (NHEJ) genes (DCLRE1C/ARTEMIS, PRKDC/DNA-PKcs, XRCC5/KU80, and XRCC6/KU70) were identified in four DLBCL tumors and cytogenetic analyses revealed that translocations involving the immunoglobulin-heavy chain locus occurred exclusively in NHEJ-mutated samples. The novel mutation targets, CHEK2 and PARP1, were further screened in expanded DLBCL cohorts, and somatic as well as novel and rare germline mutations were identified in 8 and 5% of analyzed tumors, respectively. By correlating defects in a subset of DNA damage response and repair genes with genomic instability events in tumors, we propose that these genes play a role in DLBCL lymphomagenesis.</p>
  •  
3.
  • de Miranda, Noel F. C. C., et al. (författare)
  • DNA repair genes are selectively mutated in diffuse large B cell lymphomas
  • 2013
  • Ingår i: Journal of Experimental Medicine. - 0022-1007 .- 1540-9538. ; 210:9, s. 1729-1742
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>DNA repair mechanisms are fundamental for B cell development, which relies on the somatic diversification of the immunoglobulin genes by V(D)J recombination, somatic hypermutation, and class switch recombination. Their failure is postulated to promote genomic instability and malignant transformation in B cells. By performing targeted sequencing of 73 key DNA repair genes in 29 B cell lymphoma samples, somatic and germline mutations were identified in various DNA repair pathways, mainly in diffuse large B cell lymphomas (DLBCLs). Mutations in mismatch repair genes (EXO1, MSH2, and MSH6) were associated with microsatellite instability, increased number of somatic insertions/deletions, and altered mutation signatures in tumors. Somatic mutations in nonhomologous end-joining (NHEJ) genes (DCLRE1C/ARTEMIS, PRKDC/DNA-PKcs, XRCC5/KU80, and XRCC6/KU70) were identified in four DLBCL tumors and cytogenetic analyses revealed that translocations involving the immunoglobulin-heavy chain locus occurred exclusively in NHEJ-mutated samples. The novel mutation targets, CHEK2 and PARP1, were further screened in expanded DLBCL cohorts, and somatic as well as novel and rare germline mutations were identified in 8 and 5% of analyzed tumors, respectively. By correlating defects in a subset of DNA damage response and repair genes with genomic instability events in tumors, we propose that these genes play a role in DLBCL lymphomagenesis.</p>
  •  
4.
  • Johansson, Henrik, et al. (författare)
  • Targeted resequencing of candidate genes using Selector Probes
  • 2011
  • Ingår i: Nucleic Acids Research. - 0305-1048 .- 1362-4962. ; 39:2, s. e8
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Targeted genome enrichment is a powerful tool for making use of the massive throughput of novel DNA-sequencing instruments. We herein present a simple and scalable protocol for multiplex amplification of target regions based on the Selector technique. The updated version exhibits improved coverage and compatibility with next-generation-sequencing (NGS) library-construction procedures for shotgun sequencing with NGS platforms. To demonstrate the performance of the technique, all 501 exons from 28 genes frequently involved in cancer were enriched for and sequenced in specimens derived from cell lines and tumor biopsies. DNA from both fresh frozen and formalin-fixed paraffin-embedded biopsies were analyzed and 94 specificity and 98 coverage of the targeted region was achieved. Reproducibility between replicates was high (R <sup>2</sup>=0, 98) and readily enabled detection of copy-number variations. The procedure can be carried out in &lt;24 h and does not require any dedicated instrumentation.</p>
  •  
5.
  • La Fleur, Linnéa, et al. (författare)
  • Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
  • 2019
  • Ingår i: Lung Cancer. - 0169-5002 .- 1872-8332. ; 130, s. 50-58
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Objectives: Non-small cell lung cancer (NSCLC) is a heterogeneous disease with unique combinations of somatic molecular alterations in individual patients, as well as significant differences in populations across the world with regard to mutation spectra and mutation frequencies. Here we aim to describe mutational patterns and linked clinical parameters in a population-based NSCLC cohort. Materials and methods: Using targeted resequencing the mutational status of 82 genes was evaluated in a consecutive Swedish surgical NSCLC cohort, consisting of 352 patient samples from either fresh frozen or formalin fixed paraffin embedded (FFPE) tissues. The panel covers all exons of the 82 genes and utilizes reduced target fragment length and two-strand capture making it compatible with degraded FFPE samples. Results: We obtained a uniform sequencing coverage and mutation load across the fresh frozen and FFPE samples by adaption of sequencing depth and bioinformatic pipeline, thereby avoiding a technical bias between these two sample types. At large, the mutation frequencies resembled the frequencies seen in other western populations, except for a high frequency of KRAS hotspot mutations (43%) in adenocarcinoma patients. Worse overall survival was observed for adenocarcinoma patients with a mutation in either TP53, STK11 or SMARCA4. In the adenocarcinoma KRAS-mutated group poor survival appeared to be linked to concomitant TP53 or STK11 mutations, and not to KRAS mutation as a single aberration. Similar results were seen in the analysis of publicly available data from the cBioPortal. In squamous cell carcinoma a worse prognosis could be observed for patients with MLL2 mutations, while CSMD3 mutations were linked to a better prognosis. Conclusion: Here we have evaluated the mutational status of a NSCLC cohort. We could not confirm any survival impact of isolated driver mutations. Instead, concurrent mutations in TP53 and STK11 were shown to confer poor survival in the KRAS-positive adenocarcinoma subgroup.</p>
  •  
6.
  • La Fleur, Linnéa, et al. (författare)
  • Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
  • 2019
  • Ingår i: Lung Cancer. - Elsevier. - 0169-5002. ; 130, s. 50-58
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: Non-small cell lung cancer (NSCLC) is a heterogeneous disease with unique combinations of somatic molecular alterations in individual patients, as well as significant differences in populations across the world with regard to mutation spectra and mutation frequencies. Here we aim to describe mutational patterns and linked clinical parameters in a population-based NSCLC cohort. Materials and methods: Using targeted resequencing the mutational status of 82 genes was evaluated in a consecutive Swedish surgical NSCLC cohort, consisting of 352 patient samples from either fresh frozen or formalin fixed paraffin embedded (FFPE) tissues. The panel covers all exons of the 82 genes and utilizes reduced target fragment length and two-strand capture making it compatible with degraded FFPE samples. Results: We obtained a uniform sequencing coverage and mutation load across the fresh frozen and FFPE samples by adaption of sequencing depth and bioinformatic pipeline, thereby avoiding a technical bias between these two sample types. At large, the mutation frequencies resembled the frequencies seen in other western populations, except for a high frequency of KRAS hotspot mutations (43%) in adenocarcinoma patients. Worse overall survival was observed for adenocarcinoma patients with a mutation in either TP53, STK11 or SMARCA4. In the adenocarcinoma KRAS-mutated group poor survival appeared to be linked to concomitant TP53 or STK11 mutations, and not to KRAS mutation as a single aberration. Similar results were seen in the analysis of publicly available data from the cBioPortal. In squamous cell carcinoma a worse prognosis could be observed for patients with MLL2 mutations, while CSMD3 mutations were linked to a better prognosis. Conclusion: Here we have evaluated the mutational status of a NSCLC cohort. We could not confirm any survival impact of isolated driver mutations. Instead, concurrent mutations in TP53 and STK11 were shown to confer poor survival in the KRAS-positive adenocarcinoma subgroup.
7.
  •  
8.
  •  
9.
  • Lundin, Karin E, et al. (författare)
  • Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene
  • 2015
  • Ingår i: Clinical Immunology. - Elsevier. - 1521-6616 .- 1521-7035. ; 161:2, s. 366-372
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Phosphoglucomutase 3 (PGM3) is an enzyme converting N-acetyl-glucosamine-6-phosphate to N-acetylglucosamine-l-phosphate, a precursor important for glycosylation. Mutations in the PGM3 gene have recently been identified as the cause of novel primary immunodeficiency with a hyper-IgE like syndrome. Here we report the occurrence of a homozygous mutation in the PGM3 gene in a family with immunodeficient children, described already in 1976. DNA from two of the immunodeficient siblings was sequenced and shown to encode the same homozygous missense mutation, causing a destabilized protein with reduced enzymatic capacity. Affected individuals were highly prone to infections, but lack the developmental defects in the nervous and skeletal systems, reported in other families. Moreover, normal IgE levels were found. Thus, belonging to the expanding group of congenital glycosylation defects, PGM3 deficiency is characterized by immunodeficiency, with or without increased IgE levels, and with variable forms of developmental defects affecting other organ systems.</p>
  •  
10.
  • Lundin, Karin E., et al. (författare)
  • Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene
  • 2015
  • Ingår i: Clinical Immunology. - 1521-6616 .- 1521-7035. ; 161:2, s. 366-372
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Phosphoglucomutase 3 (PGM3) is an enzyme converting N-acetyl-glucosamine-6-phosphate to N-acetylglucosamine-l-phosphate, a precursor important for glycosylation. Mutations in the PGM3 gene have recently been identified as the cause of novel primary immunodeficiency with a hyper-IgE like syndrome. Here we report the occurrence of a homozygous mutation in the PGM3 gene in a family with immunodeficient children, described already in 1976. DNA from two of the immunodeficient siblings was sequenced and shown to encode the same homozygous missense mutation, causing a destabilized protein with reduced enzymatic capacity. Affected individuals were highly prone to infections, but lack the developmental defects in the nervous and skeletal systems, reported in other families. Moreover, normal IgE levels were found. Thus, belonging to the expanding group of congenital glycosylation defects, PGM3 deficiency is characterized by immunodeficiency, with or without increased IgE levels, and with variable forms of developmental defects affecting other organ systems.</p>
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 24
  • [1]23Nästa
Åtkomst
fritt online (6)
Typ av publikation
tidskriftsartikel (22)
annan publikation (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (18)
övrigt vetenskapligt (6)
Författare/redaktör
Nilsson, Mats, (23)
Falk-Sörqvist, Elin (21)
Botling, Johan (10)
Moens, Lotte, (10)
Micke, Patrick (10)
Sundström, Magnus, (8)
visa fler...
La Fleur, Linnéa, (7)
Ljungström, Viktor, (7)
Moens, Lotte N. (6)
Mathot, Lucy, (6)
Enblad, Gunilla, (5)
Rosenquist, Richard (5)
Sjöblom, Tobias, (5)
Smith, C. I. Edvard (5)
Isaksson, Johan, (4)
Brunnström, Hans, (4)
Lundin, Karin E. (4)
Brandén, Eva, (4)
Koyi, Hirsh, (4)
Mansouri, Larry (3)
Kalushkova, Antonia, (3)
Stamatopoulos, Kosta ... (3)
Sutton, Lesley-Ann, (3)
Ghia, Paolo, (3)
Langerak, Anton W., (3)
Belessi, Chrysoula, (3)
Davi, Frederic, (3)
Yan, Xiao-Jie (3)
Juliusson, Gunnar, (3)
Pospisilova, Sarka (3)
Chiorazzi, Nicholas (3)
Söderberg, Ola, (3)
Christensson, Birger (3)
Arngården, Linda, (3)
Smedby, Karin E. (3)
Plevova, Karla, (3)
Strefford, Jonathan ... (3)
Cortese, Diego, (3)
Young, Emma, (3)
Hellström, Mats, (3)
Bhoi, Sujata, (3)
Stenmark, Stephan, (3)
Bondza, Sina, (3)
Sander, Birgitta (3)
Gunnarsson, Rebeqa (3)
Smeds, Patrik, (3)
Sörqvist, Elin Falk, (3)
Larsson, Jimmy (3)
Mattsson, Johanna, (3)
Granert, Carl (3)
visa färre...
Lärosäte
Uppsala universitet (13)
Stockholms universitet (7)
Lunds universitet (3)
Umeå universitet (1)
Karolinska Institutet (1)
Språk
Engelska (23)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (23)
Naturvetenskap (3)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy